Previous 10 | Next 10 |
MoneyShow.com news releases related Moneyshow.com news releases and Moneyshow.com press releases from 07/29/19 06:25:00 on US and Canada Markets.
Here are four stocks to watch according to Harry Boxer . Three of them moving on strong earnings. Anika Therapeutics, Inc. ( ANIK ) popped $11.78, or 28.8%, to $52.60 on Thursday on 1.3 million shares, or about 8x its average volume. The small biotech beat analyst estimates in its...
More companies are paying dividends than ever. What’s more, these dividend payers are paying more than ever. Dividends hit a record high in 2018, explains Steve Mauzy , dividend expert and editor of High Yield Wealth . Global corporations paid $1.37 trillion in div...
Skilled management can be worth well than its expenses in any investment vehicle, asserts Brett Owens , fund specialist, income expert and editor of Contrarian Outlook . However, when you’re dealing with an inaccessible alternative field such as bank loans, a steady guid...
In rating more than 1,200 equity ETFs, CFRA Research combines proprietary holdings-level analysis with fund attributes, such as its expense ratio and technical trends, notes CFRA Research analyst Todd Rosenbluth in The Outlook . The CFRA Focus ETF for July is iShares Edge MS...
In rating more than 1,200 equity ETFs, CFRA Research combines proprietary holdings-level analysis with fund attributes, such as its expense ratio and technical trends, notes CFRA Research analyst Todd Rosenbluth in The Outlook . The CFRA Focus ETF for July is iShares Edge MS...
Central banks are fueling the bull market as expectations mount for looser policy, writes Bill Baruch. E-mini S&P (ESU) Yesterday’s close: Settled at 3021.50, up 13.50 Fundamentals: The path of least resistance is higher, this is undeniable. The U.S economic data is ...
Our model portfolio closed out the month of June above $550K, meaning the 2 for 1 portfolio has grown 1000% since its inception 23 years ago; that’s an 11% annualized return, explains Neil Macneale , editor of 2-for-1 Stock Split Newsletter . Our long-standing practice ...
In a major coup for Ziopharm Oncology ( ZIOP ), the company has attracted the services of Drew Deniger, Ph.D., from the National Cancer Institute (NCI) to lead the company’s program to genetically modify T-cells to express neoantigen-specific T-cell receptors (TCRs), effective Ju...
Housing stocks have been a hit and miss affair all year, but there are two companies which should benefit from the current economic climate as long as bond yields and mortgage rates don’t start a nasty rising cycle and the job market doesn’t collapse, explains Joe Duarte , ...
Our macro themes are intended to focus your attention on the global macro trends that matter most, writes Landon Whaley , who breaks down his approach and performance. Capturing economic and financial market data and contextualizing it is something the Old Institution and its followers f...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
15.84%Change Percent:
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
lexpharma.com Website: